EconPapers    
Economics at your fingertips  
 

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Anju Murayama (), Sae Kamamoto (), Hiroaki Saito (), Kohki Yamada (), Divya Bhandari (), Iori Shoji (), Hanano Mamada (), Moe Kawashima (), Erika Yamashita (), Eiji Kusumi (), Toyoaki Sawano (), Binaya Sapkota (), Tetsuya Tanimoto () and Akihiko Ozaki ()
Additional contact information
Anju Murayama: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Sae Kamamoto: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Hiroaki Saito: Department of Gastroenterology, Sendai Kosei Hospital, Sendai City 980-0873, Miyagi, Japan
Kohki Yamada: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Divya Bhandari: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Iori Shoji: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Hanano Mamada: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Moe Kawashima: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Erika Yamashita: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Eiji Kusumi: Navitas Clinic Shinjuku, Shinjuku-ku 160-0022, Tokyo, Japan
Toyoaki Sawano: Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City 972-8322, Fukushima, Japan
Binaya Sapkota: Nobel College Faculty of Health Sciences, Pokhara University, Kathmandu 33700, Nepal
Tetsuya Tanimoto: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan
Akihiko Ozaki: Medical Governance Research Institute, Minato-ku 108-0074, Tokyo, Japan

IJERPH, 2022, vol. 19, issue 12, 1-13

Abstract: Backgrounds: Conflict of interest with pharmaceutical companies is one of the most concerned issues in infectious diseases. However, there is a lack of whole picture of detailed payments in Japan. Methods: This retrospective study assessed financial relationships between pharmaceutical companies and all infectious disease specialists board-certified by the Japanese Association for Infectious Disease, using publicly disclosed payment data from 92 major pharmaceutical companies. Descriptive analyses were conducted for the payments. Payment trends were examined by the generalized estimating equations. Results: Of 1614 board-certified infection disease specialists, 1055 (65.4%) received a total of $17,784,070 payments, corresponding to 21,680 contracts between 2016 and 2019. The mean ± SD and median (interquartile range: IQR) were $16,857 ± $45,010 and $3183 ($938–$11,250) in payments. All board executive members of Japanese Association of Infectious Disease received higher payments averaging $163,792. There were no significant changes in payments per specialist (annual change rate: −1.4% [95% CI: −4.7–2.3%], p = 0.48) and prevalence of specialists with payments (annual change rate: −1.4% [95% CI: −3.1–0.2%], p = 0.093) over the four years. Conclusion: There were substantial financial relationships between pharmaceutical companies and board-certified infectious disease specialists in Japan. Furthermore, high ranked specialists such as those in the executive board had stronger financial ties with the companies.

Keywords: board-certified infectious disease specialists; pharmaceutical payments; physician payment; conflicts of interest; Japan (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/12/7417/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/12/7417/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:12:p:7417-:d:840533

Access Statistics for this article

IJERPH is currently edited by Ms. Arlene Chen

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().

 
Page updated 2022-10-15
Handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7417-:d:840533